Literature DB >> 21206329

GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.

Olca Basturk1, Rajendra Singh, Ecmel Kaygusuz, Serdar Balci, Nevra Dursun, Nil Culhaci, N Volkan Adsay.   

Abstract

OBJECTIVES: GLUT-1 has been found to have an important role in the upregulation of various cellular pathways and implicated in neoplastic transformation correlating with biological behavior in malignancies. However, literature regarding the significance of GLUT-1 expression in pancreatic neoplasia has been limited and controversial.
METHODS: Immunohistochemical expression of GLUT-1 was tested in a variety of pancreatic neoplasia including ductal adenocarcinomas (DAs), pancreatic intraepithelial neoplasms (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and serous cystadenomas.
RESULTS: There was a progressive increase in the expression of GLUT-1 from low- to higher-grade dysplastic lesions: All higher-grade PanINs/IPMNs (the ones with moderate/high-grade dysplasia) revealed noticeable GLUT-1 expression. Among the 94 DAs analyzed, there were minimal/moderate expression in 46 and significant expression in 24 DAs. However, all 4 clear-cell variants of DAs revealed significant GLUT-1 immunolabeling, as did areas of clear-cell change seen in other DAs. Moreover, all 12 serous cystadenomas expressed significant GLUT-1. GLUT-1 expression was also directly correlated with DA histological grade (P = 0.016) and tumor size (P = 0.03).
CONCLUSIONS: GLUT-1 may give rise to the distinctive clear-cell appearance of these tumors by inducing the accumulation of glycogen in the cytoplasm. Additionally, because GLUT-1 expression was related to histological grade and tumor size of DA, further studies are warranted to investigate the association of GLUT-1 with prognosis and tumor progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21206329      PMCID: PMC3164314          DOI: 10.1097/MPA.0b013e318201c935

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  43 in total

1.  Over-expression of facilitative glucose transporter genes in human cancer.

Authors:  T Yamamoto; Y Seino; H Fukumoto; G Koh; H Yano; N Inagaki; Y Yamada; K Inoue; T Manabe; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1990-07-16       Impact factor: 3.575

2.  Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.

Authors:  T Higashi; N Tamaki; T Honda; T Torizuka; T Kimura; T Inokuma; G Ohshio; R Hosotani; M Imamura; J Konishi
Journal:  J Nucl Med       Date:  1997-09       Impact factor: 10.057

3.  Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6).

Authors:  T Kayano; C F Burant; H Fukumoto; G W Gould; Y S Fan; R L Eddy; M G Byers; T B Shows; S Seino; G I Bell
Journal:  J Biol Chem       Date:  1990-08-05       Impact factor: 5.157

4.  18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma.

Authors:  B Nakata; Y S Chung; S Nishimura; T Nishihara; Y Sakurai; T Sawada; T Okamura; J Kawabe; H Ochi; M Sowa
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

5.  Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia.

Authors:  C Chen; N Pore; A Behrooz; F Ismail-Beigi; A Maity
Journal:  J Biol Chem       Date:  2000-12-18       Impact factor: 5.157

6.  GLUT1 expression in human breast carcinoma: correlation with known prognostic markers.

Authors:  M Younes; R W Brown; D R Mody; L Fernandez; R Laucirica
Journal:  Anticancer Res       Date:  1995 Nov-Dec       Impact factor: 2.480

7.  Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression.

Authors:  X Z Ding; D M Fehsenfeld; L O Murphy; J Permert; T E Adrian
Journal:  Pancreas       Date:  2000-10       Impact factor: 3.327

8.  Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis.

Authors:  Irem H Ozbudak; Konstantin Shilo; Fabio Tavora; Negar Rassaei; Wei-Sing Chu; Junya Fukuoka; Jin Jen; William D Travis; Teri J Franks
Journal:  Mod Pathol       Date:  2009-02-20       Impact factor: 7.842

9.  Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity.

Authors:  Hiromichi Ito; Mark Duxbury; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

10.  The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia.

Authors:  E M Cornford; S Hyman; B E Swartz
Journal:  J Cereb Blood Flow Metab       Date:  1994-01       Impact factor: 6.200

View more
  29 in total

1.  Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma.

Authors:  Ashley H Davis-Yadley; Andrea M Abbott; Jose M Pimiento; Dung-Tsa Chen; Mokenge P Malafa
Journal:  Pancreas       Date:  2016-08       Impact factor: 3.327

2.  Development of photoactive Sweet-C60 for pancreatic cancer stellate cell therapy.

Authors:  Maciej Serda; Matthew J Ware; Jared M Newton; Sanchit Sachdeva; Martyna Krzykawska-Serda; Lam Nguyen; Justin Law; Andrew O Anderson; Steven A Curley; Lon J Wilson; Stuart J Corr
Journal:  Nanomedicine (Lond)       Date:  2018-12-03       Impact factor: 5.307

Review 3.  Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.

Authors:  Yu-Ping Xu; Min Yang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 4.  Benign Tumors and Tumorlike Lesions of the Pancreas.

Authors:  Olca Basturk; Gokce Askan
Journal:  Surg Pathol Clin       Date:  2016-12

5.  Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery.

Authors:  Xinqun Li; Mark A Truty; Ya'an Kang; Xavier Chopin-Laly; Ran Zhang; David Roife; Deyali Chatterjee; E Lin; Ryan M Thomas; Huamin Wang; Matthew H Katz; Jason B Fleming
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

6.  High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma.

Authors:  Lauren E Colbert; Sarah B Fisher; Serdar Balci; Burcu Saka; Zhengjia Chen; Sungjin Kim; Bassel F El-Rayes; N Volkan Adsay; Shishir K Maithel; Jerome C Landry; Walter J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-13       Impact factor: 7.038

Review 7.  Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.

Authors:  Abudureyimu Tuerhong; Jin Xu; Si Shi; Zhen Tan; Qingcai Meng; Jie Hua; Jiang Liu; Bo Zhang; Wei Wang; Xianjun Yu; Chen Liang
Journal:  Cell Mol Life Sci       Date:  2021-06-15       Impact factor: 9.261

Review 8.  Glucose transporters in cancer metabolism.

Authors:  Kehinde Adekola; Steven T Rosen; Mala Shanmugam
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

9.  Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.

Authors:  I-Lu Lai; Chih-Chien Chou; Po-Ting Lai; Chun-Sheng Fang; Lawrence A Shirley; Ribai Yan; Xiaokui Mo; Mark Bloomston; Samuel K Kulp; Tanios Bekaii-Saab; Ching-Shih Chen
Journal:  Carcinogenesis       Date:  2014-05-30       Impact factor: 4.944

Review 10.  Glucose metabolic phenotype of pancreatic cancer.

Authors:  Anthony K C Chan; Jason I E Bruce; Ajith K Siriwardena
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.